Antigen polypeptide and its application
By extracting and isolating antigenic peptides from cystic tissue of Echinococcus fine-grained Echinococcus cystic tissue, the problem of false positive and false negative in hydatis disease is solved, the specificity and sensitivity of the diagnosis is improved, and large-scale screening is supported to achieve high purity Application of antigenic polypeptides.
Patent Information
- Application Number
- CN202311664133.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-12-06
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2043-12-06
AI Technical Summary
In the prior art, serological testing of hydatosis is prone to produce false positive or false negative results, and a single antigen is lacking for effective diagnosis.
By extracting HLA-I and HLA-II antibodies from the cystic tissue of Echinococcus fines, high-purity antigen peptides were isolated and screened using immunoprecipitation technology, and combined with high performance liquid chromatography and mass spectrometry analysis, high binding was obtained by obtaining high binding Antigenic polypeptides with excellent immunogenicity.
It improves the specificity and sensitivity of hydatosis diagnosis, provides high-purity antigenic peptides for vaccine preparation and diagnosis, reduces false positive or false negative results, and supports large-scale screening.
Smart Images

Figure CN117903274B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of immunobiological technology, and in particular to an antigen polypeptide and application thereof. Background Art
[0002] Hydatid disease (cystic echinococcosis; CE), also known as echinococcosis, is a serious zoonosis caused by the larvae of Echinococcus granulosus (Echinococcus granulosus; Eg) parasitizing the liver, lungs, brain and other tissues and organs of the human body and some animals, which seriously endangers people's health and the development of animal husbandry.
[0003] Imaging is a common method for diagnosing echinococcosis. However, due to the long incubation period of echinococcosis and the fact that cysts formed by echinococcosis can only be detected by imaging when they are large enough, serological testing is needed as an important supplement to imaging testing. At present, commercial echinococcosis antigens are natural purified antigens, which are separated and purified from soluble antigen fragments after the cysts are crushed. They are a mixture of multiple echinococcosis proteins. The more mixed proteins are, the more likely it is to produce more false positive or false negative results in serological testing.
[0004] Obtaining a single antigen for echinococcosis detection and reducing false positive or false negative results has become an urgent problem to be solved. Summary of the invention
[0005] In view of the above-mentioned defects of the prior art, the present invention provides an antigen polypeptide with higher purity, which can be used for serological detection of echinococcosis, thereby expanding the selection range of antigen polypeptides; to this end, the present invention also provides an application of the above-mentioned antigen polypeptide in the preparation of products for diagnosing, treating or preventing echinococcosis.
[0006] In order to solve the above technical problems, the first aspect of the present invention provides an antigen polypeptide, which comprises one or more of the amino acid sequences shown in SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3.
[0007] As a preferred embodiment, the antigenic polypeptide is from Echinococcus granulosus.
[0008] The second aspect of the present invention provides a method for preparing the above antigen polypeptide, comprising the following steps:
[0009] S1. Adding HLA-I antibody or HLA-II antibody to the lysed sample of liver cyst tissue of patients with echinococcosis to immunoprecipitate HLA-peptides;
[0010] S2. Separate and screen the antibody-HLA protein and polypeptide to obtain the above-mentioned antigen polypeptide.
[0011] As a preferred embodiment, the screening in step S2 includes universal screening and immunogenicity determination.
[0012] Through the immunoprecipitation technique, HLA-peptides were immunoprecipitated from cell lysates using HLA-I and HLA-II antibodies, and then the antibody-HLA protein and peptide were separated to obtain purified peptides. This method can obtain 179 peptides, 105 of which are from Echinococcus in HLA I binding peptides and 74 of which are from Echinococcus in HLA II binding peptides. Not all peptides obtained can be used for vaccines and echinococcosis diagnosis. Further universality and immunogenicity studies were conducted to finally obtain the above three antigenic peptides.
[0013] The antigen polypeptide prepared by this method has high binding affinity with HLA-I and HLA-II molecules and excellent immunogenicity, and is of high purity, and can be used for vaccine preparation and diagnosis of echinococcosis.
[0014] The third aspect of the present invention provides an isolated nucleic acid encoding the above-mentioned antigenic polypeptide.
[0015] The fourth aspect of the present invention provides a recombinant expression vector comprising the above-mentioned nucleic acid.
[0016] The fifth aspect of the present invention provides a cell comprising the above-mentioned antigen polypeptide, the above-mentioned nucleic acid or the above-mentioned recombinant expression vector.
[0017] The sixth aspect of the present invention provides a use of the above-mentioned antigen polypeptide, the above-mentioned nucleic acid, the above-mentioned recombinant expression vector or the above-mentioned cell in the preparation of a product for diagnosing, treating or preventing echinococcosis.
[0018] According to a seventh aspect of the present invention, a kit for detecting echinococcosis is provided, wherein the kit comprises the above-mentioned antigen polypeptide.
[0019] The eighth aspect of the present invention provides a vaccine for echinococcosis, which comprises the above-mentioned antigen polypeptide, the above-mentioned nucleic acid, the above-mentioned recombinant expression vector or the above-mentioned cell.
[0020] As a preferred embodiment, the vaccine further comprises an immunologically acceptable carrier.
[0021] As a preferred embodiment, the immunologically acceptable carrier includes an adjuvant, a diluent, a solubilizer, a lubricant, a suspending agent, a transfection accelerator, an excipient, a filler, a binder, an absorption promoter and / or a synergist.
[0022] The ninth aspect of the present invention provides a method for preparing a vaccine, which comprises mixing the above-mentioned antigen polypeptide with an immunologically acceptable carrier.
[0023] Compared with the prior art, the present invention has the following beneficial effects:
[0024] (1) The antigenic polypeptide of the present invention has a purity of up to 99%, which enriches the single antigen database of echinococcosis and provides room for improving the specificity and sensitivity of laboratory diagnosis of echinococcosis.
[0025] (2) The antigenic polypeptide of the present invention has high binding affinity and stability with HLA-I\II class molecules and can be used for the prevention, diagnosis and treatment of Echinococcus granulosus.
[0026] (3) The antigenic polypeptide of the present invention can be synthesized in large quantities by chemical means, which provides the possibility for large-scale screening of human echinococcosis.
[0027] The concept, specific structure and technical effects of the present invention will be further described below in conjunction with the accompanying drawings to fully understand the purpose, characteristics and effects of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 This is a mass error distribution diagram of the peptide segment detected in the mass spectrometry analysis results of Example 1 of the present invention.
[0029] Figure 2 These are the HPLC chromatogram and mass spectrum of the antigen polypeptide P1 of Example 2 of the present invention, wherein 2A is the HPLC chromatogram and 2B is the mass spectrum.
[0030] Figure 3 These are the HPLC chromatogram and mass spectrum of the antigen polypeptide P2 of Example 2 of the present invention, wherein 3A is the HPLC chromatogram and 3B is the mass spectrum.
[0031] Figure 4 These are the HPLC chromatogram and mass spectrum of the antigen polypeptide P3 of Example 2 of the present invention, wherein 4A is the HPLC chromatogram and 4B is the mass spectrum.
[0032] Figure 5 This is a spectrum of the proliferation effect of BMDCs detected by the CCK-8 method in Example 3 of the present invention, in which * indicates P<0.05 and **** indicates P<0.0001. DETAILED DESCRIPTION
[0033] In order to make the technical means, creative features, objectives and effects of the invention easier to understand, the invention is further described below with reference to specific illustrations. However, the invention is not limited to the following implementation cases.
[0034] It should be noted that the structures, proportions, sizes, etc. illustrated in the drawings of this specification are only used to match the contents disclosed in the specification for people familiar with this technology to understand and read, and are not used to limit the conditions under which the present invention can be implemented. Therefore, they have no substantive technical significance. Any modification of the structure, change in the proportion relationship or adjustment of the size should fall within the scope of the technical content disclosed in the present invention without affecting the effects and purposes that can be achieved by the present invention.
[0035] Example 1 Screening of Antigenic Peptides
[0036] The screening steps for antigenic peptides are as follows:
[0037] 1. Grind the liver cysts of patients with echinococcosis who underwent surgical resection with liquid nitrogen and perform ultrasonic fragmentation;
[0038] 2. Add immunoprecipitation cell lysis buffer (IPlysis buffer, which is PBS buffer, including 0.25% sodium deoxycholate, 0.2mM iodoacetamide, 1mM EDTA, 1:200 protease inhibitor mixture (sigma, product number 539131), 1mM phenylmethylsulfonyl fluoride and 1% octyl glucoside (sigma), the above percentages are weight percentages) at a ratio of 0.5g sample to 0.5ml lysis buffer;
[0039] 3. Lyse at 4°C for 2 hours to obtain tissue lysate samples;
[0040] 4. Centrifuge the tissue lysate sample at 24000g for 1.5 hours at 4°C. After centrifugation, transfer the supernatant to a new EP tube and add 20 μg of HLA-I pan antibody (HLA-I pan antibody is type I human leukocyte antigen, purchased from Jingjie Bio, and the HLA-I pan antibody is purified from W632 hybridoma);
[0041] 5. Incubate at 4°C for 1 hour. After the incubation, transfer the supernatant to a new EP tube, add 10 μL of protein A / G magnetic beads (Protein A / G beads, purchased from GenScript Biotech Co., Ltd., model: Protein A / G MagbeadsMX L00894) and continue incubating for 1 hour.
[0042] 6. After the incubation, centrifuge at 1000 rpm for 1 minute to obtain the protein A / G magnetic beads bound to the HLA-I antibody. Wash the magnetic beads three times with wash buffer (including 400 mM NaCl solution and 20 mM Tris-HCl buffer). Finally, use elution buffer (0.1 mol / L acetic acid aqueous solution) to elute the antibody-HLA-I-peptide from the magnetic beads.
[0043] 7. The supernatant in step 4 was transferred to a new EP tube, and 20 μg of HLA-II pan-antibody (purchased from Jingjie Bio, the HLA-II pan-antibody was purified from IVA12 hybridoma) was added to continue the second round of IP experiment;
[0044] 8. The subsequent steps of the HLA-II IP experiment started in step 7 are the same as steps 4-6;
[0045] 9. The eluted product was ultrafiltered with an ultrafilter (purchased from Biopac Biotech) with a cutoff of 10 kD. The flowthrough was the polypeptide. The polypeptide was freeze-dried using a speed vacuum (using a vacuum centrifugal concentrator from Eppendorf, Germany).
[0046] 10. Desalt the drained polypeptide and then freeze-dry it in vacuum;
[0047] 11. Dissolve the peptide and perform LC-MS analysis;
[0048] 12. Liquid chromatography separation conditions: C18 chromatographic column (1.9 μm, 250 mm×75 μm), column temperature, room temperature; flow rate, 300 nL / min; liquid phase composition: phase A 0.1% formic acid aqueous solution, phase B: 0.1% formic acid acetonitrile solution; mass spectrometry parameter settings: ion source voltage, 2.0 KV; mass analysis range 350-1800 m / z; ion transfer tube temperature, 320°C; Mascot software was used to analyze the data obtained by LC-MS (nano-ultra-high performance liquid chromatograph coupled to quadrupole-orbital hydrazine-ion trap three-in-one mass spectrometer).
[0049] Through the above-mentioned antigen peptide screening process, hundreds of antigen peptides can be detected, but not all antigen peptides can be used for vaccine, diagnosis and treatment research. Therefore, hundreds of antigen peptides need to be accurately screened, and the selection of screening methods is the key to success or failure. Improper screening method design or excessive number of antigen peptides obtained will cause great obstacles to subsequent experimental processes; or it will lead to the inability to obtain the optimal antigen peptide.
[0050] The present invention completes the screening through two steps. In the first step, the 179 antigen polypeptides obtained are subjected to universality study to remove antigen polypeptides with relatively poor universality; in the second step, the antigen polypeptides screened in the first step are subjected to immunogenicity study to further verify the immunogenicity of the obtained antigen polypeptides.
[0051] The process of universal screening is as follows:
[0052] Liver tissue samples surgically removed from 6 patients with echinococcosis caused by Echinococcus granulosus were collected, and 179 peptides derived from Echinococcus granulosus were obtained through the above-mentioned peptide screening. The screened peptides were matched with the sample sources to determine the universality of the samples.
[0053] The results of the universal screening are as follows:
[0054] The results showed that antigenic peptide P1: FLQSEQLT existed in all six samples and had the best universality; antigenic peptides P2: FEQEMATAA and P3: AFIDTEVAAT existed in three samples at the same time; and there were 7 antigenic peptides that existed in two samples at the same time, all of which had good universality. Other antigenic peptides only existed in one sample, and the universality of antigenic peptides was weak.
[0055] Through universality comparison, it was found that ten antigenic peptides existed in at least two samples. The immunogenicity of the top three antigenic peptides with the best universality (antigenic polypeptides P1, P2, and P3, whose amino acid sequences are shown in SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, respectively) was determined (determination method in Example 3), and the immunogenicity was strong. The amino acid sequences of the three antigenic peptides, the corresponding HLA molecule types, the gene names of the encoded peptides, the mass-to-charge ratio of the peptides, and the actual mass of the peptides are shown in Table 1.
[0056] Table 1 Sequences and related features of three antigenic peptides
[0057]
[0058] In order to ensure the accuracy of the measurement results, the mass error distribution of the peptides in the mass spectrometry analysis results is examined. The score of the spectrum matching peptide (characterizing the credibility of the peptide identification) is negatively correlated with the distribution of mass deviation; the higher the score, the smaller the mass deviation. The mass error distribution diagram of the peptides in the mass spectrometry analysis results of this application is shown in Figure 1. Figure 1 As shown. Figure 1 It can be seen that the primary mass error of most spectra is within 0.01Da, which is consistent with the high-precision characteristics of orbital trap mass spectrometry, indicating that the mass accuracy of the mass spectrometer is normal and will not affect the qualitative and quantitative analysis of the protein due to excessive mass deviation.
[0059] Example 2 Chemical synthesis and characterization of antigenic polypeptides
[0060] Antigen peptides P1, P2, and P3 were artificially synthesized by Sinopeptide Biochemical Co., Ltd., and their purity and molecular weight were analyzed by high performance liquid chromatography (HPLC) and mass spectrometry (MS).
[0061] After chemical synthesis, HPLC test results showed that the antigen peptide P1 had a peptide peak at 10.520 min, with a purity of 99.3%. MS analysis showed that the molecular weight of P1 was 965.1 g / mol ( Figure 2 AB); P2 showed a peptide peak at 8.586 min, with a purity of 98.8%. The molecular weight of P2 was 997.1 g / mol ( Figure 3 AB); P3 showed a peptide peak at 7.260 min, with a purity of 99.7%. The molecular weight of P3 was 1037.1 g / mol ( Figure 4 AB).
[0062] Example 3 Study on the immunogenicity of antigenic polypeptides
[0063] (1) Isolation and culture of mouse bone marrow-derived dendritic cells
[0064] ① 6-8 week old C57BL / 6 mice (purchased from Shanghai Jihui Experimental Animal Breeding Co., Ltd.) were taken and anesthetized by intraperitoneal injection of 0.1% sodium pentobarbital. The mice were killed by cervical dislocation and disinfected by immersion in 75% alcohol. The femur and tibia of the mice were separated under a sterile environment. RPMI-1640 cell culture medium was drawn with a 1 ml syringe to flush the bone marrow cavity 4-6 times, and filtered with a 100 μm mesh until the bone cavity flushed white;
[0065] ② Centrifuge the cell suspension (4°C, 350×g, 5 min), discard the supernatant, resuspend the precipitate with red blood cell lysis buffer, lyse for 2-3 min, and prepare RPMI-1640 complete medium (containing 10% fetal bovine serum, 1% penicillin and streptomycin) to resuspend;
[0066] ③ Adjust the cell concentration of the separated cell suspension to 1×10 6 / ml, mouse granulocyte colony stimulating factor rmGM-CSF and mouse interleukin cytokine IL-4 (purchased from Peprotech, USA) were added at working concentrations of 20ng / ml and 10ng / ml, respectively, and cultured in 6-well plates and placed in a 37°C, 5% CO2 incubator for culture;
[0067] ④ On the third and fifth days of culture, half of the medium was replaced and cytokines rmGM-CSF and IL-4 were supplemented;
[0068] ⑤ After culturing for the seventh day, all the suspended cells were collected, which were mouse bone marrow-derived dendritic cells (BMDCs).
[0069] (2) CCK-8 method to detect the proliferation effect of BMDCs in vitro
[0070] ① Collect BMDCs isolated and cultured on the seventh day and adjust the cell concentration to 1×10 6 / ml, supplemented with cytokines rmGM-CSF and IL-4, cultured in 96-well plates, 100 μl per well;
[0071] ② The experimental groups were added with 10 μg / ml of P1, P2, and P3 peptides, LPS (stimulation concentration 0.5 μg / ml) as the positive control group (LPS can significantly induce the proliferation of BMDCs), and the phosphate buffered saline (PBS) group was the negative control group, and cultured in a 37°C, 5% CO2 incubator for 48 hours;
[0072] ③ Add 10 μl of CCK-8 reagent to each well, culture in the incubator for 2 to 3 hours, detect the absorbance at 450 nm with an enzyme-labeled instrument, and calculate the cell viability.
[0073] The results showed that after 48 hours of in vitro treatment of BMDCs, the absorbance values of lipopolysaccharide (LPS) as the positive control group, peptide stimulation group P1, group P2 and group P3 at 450nm were (1.48±0.02), (1.37±0.01), (1.38±0.00) and (1.30±0.01), respectively, which were significantly different from the negative control group (1.26±0.01) (P<0.05), indicating that the three antigenic peptides (P1-P3) all have the ability to stimulate the proliferation of BMDCs in vitro (such as Figure 5 shown).
[0074] The preferred specific embodiments of the present invention are described in detail above. It should be understood that ordinary technicians in the field can make many modifications and changes based on the concept of the present invention without creative work. Therefore, all technical solutions that can be obtained by technicians in the technical field based on the concept of the present invention through logical analysis, reasoning or limited experiments on the basis of the prior art should be within the scope of protection determined by the claims.
Claims
1. An antigen polypeptide, characterized in that The antigen polypeptide is one or more of the amino acid sequences shown in SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO:
3.
2. The antigen polypeptide according to claim 1, characterized in that The antigenic polypeptide is derived from Echinococcus granulosus.
3. An isolated nucleic acid, characterized in that The isolated nucleic acid encodes the antigenic polypeptide of claim 1.
4. A recombinant expression vector, characterized in that: Comprising the nucleic acid of claim 3.
5. A cell comprising the antigen polypeptide of claim 1, the nucleic acid of claim 3 or the recombinant expression vector of claim 4.
6. Use of the antigen polypeptide according to claim 1, the nucleic acid according to claim 3, the recombinant expression vector according to claim 4 or the cell according to claim 5 in the preparation of a product for diagnosing echinococcosis.
7. A kit for detecting echinococcosis, characterized in that: The kit comprises the antigen polypeptide according to claim 1.
